Lung Cancer Research: 5-Year Survival Data for Alectinib
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
For patients with ALK-positive Non-Small Cell Lung Cancer (NSCLC), the ALEX trial reported 5-year follow-up data for Alectinib. These are published study results and do not mean every patient will have the same outcome.
1. Reported 5-Year Data
The trial reported a 5-year overall survival rate of 62.5% and a median PFS of 34.8 months in the Alectinib group.
2. Central Nervous System (CNS) Data
The trial also reported data on central nervous system (CNS) metastases. Whether a treatment is suitable depends on each patient's condition and must be decided by the treating physician.
Medical Supporter: Coordination Support
Medical Supporter helps coordinate communication with Japanese medical institutions. Treatment decisions are made by the treating physician.
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.